KRISTI WEBER: Open Payments
NPI 1023207040 · YORK, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 44 payments from 11 companies in 2025. Trend: 2023 $772 · 2024 $487 · 2025 $784
Food & beverage: $784
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $242 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $170 |
| Teva Pharmaceuticals USA, Inc. | 6 | $119 |
| ABBVIE INC. | 4 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
| ACADIA Pharmaceuticals Inc | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Biogen, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
Products named: CAPLYTA, ABILIFY MAINTENA, REXULTI, AUSTEDO XR, VRAYLAR, INGREZZA, UZEDY, COBENFY.
Industry payments across NE — which companies pay providers there.
